Literature DB >> 11884559

Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

John T West1, Sally K Weldon, Stephanie Wyss, Xiaoxu Lin, Qin Yu, Markus Thali, Eric Hunter.   

Abstract

The human immunodeficiency virus type 1 transmembrane glycoprotein (TM) is efficiently endocytosed in a clathrin-dependent manner. Internalization is mediated by a tyrosine-containing motif within the cytoplasmic domain, and replacement of the cytoplasmic tyrosine by cysteine or phenylalanine increased expression of mutant glycoprotein on the surface of transfected cells by as much as 2.5-fold. Because interactions between the cytoplasmic domain of Env and the matrix protein (MA) have been suggested to mediate incorporation of Env in virus particles, we examined whether perturbation of endocytosis would alter incorporation. Proviruses were constructed to contain the wild-type or mutant Env in conjunction with point mutations in MA that had previously been shown to block Env incorporation. These constructs were used to evaluate the effect of glycoprotein endocytosis on incorporation into virus particles and to test the necessity for a specific interaction between Env and MA to mediate incorporation. Viruses produced from transfected 293T cells were used to infect various cell lines, including MAGI, H9, and CEMx174. Viruses encoding both a disrupted endocytosis motif signal and mutations within MA were significantly more infectious in MAGI cells than their counterparts encoding a mutant MA and wild-type Env. This complementation of infectivity for the MA incorporation mutant viruses was not due to increased glycoprotein incorporation into particles but instead reflected an enhanced fusogenicity of the mutated Env proteins. Our findings further support the concept that a specific interaction between the long cytoplasmic domain of TM and MA is required for efficient incorporation of Env into assembling virions. Alteration of the endocytosis signal of Env, and the resulting increase in cell surface glycoprotein, has no effect on incorporation despite demonstrable effects on fusion, virus entry, and infectivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884559      PMCID: PMC136014          DOI: 10.1128/jvi.76.7.3338-3349.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.

Authors:  T Wilk; T Pfeiffer; V Bosch
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

3.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Authors:  M J Mulligan; G V Yamshchikov; G D Ritter; F Gao; M J Jin; C D Nail; C P Spies; B H Hahn; R W Compans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Transferrin receptor internalization sequence YXRF implicates a tight turn as the structural recognition motif for endocytosis.

Authors:  J F Collawn; M Stangel; L A Kuhn; V Esekogwu; S Q Jing; I S Trowbridge; J A Tainer
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

6.  Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus.

Authors:  L Rasmussen; J K Battles; W H Ennis; K Nagashima; M A Gonda
Journal:  Virology       Date:  1990-10       Impact factor: 3.616

7.  The essential tyrosine of the internalization signal in lysosomal acid phosphatase is part of a beta turn.

Authors:  W Eberle; C Sander; W Klaus; B Schmidt; K von Figura; C Peters
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

8.  The NPXY internalization signal of the LDL receptor adopts a reverse-turn conformation.

Authors:  A Bansal; L M Gierasch
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

9.  Human immunodeficiency virus (HIV) type 1 can superinfect HIV-2-infected cells: pseudotype virions produced with expanded cellular host range.

Authors:  M Le Guern; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  Transplanted LDL and mannose-6-phosphate receptor internalization signals promote high-efficiency endocytosis of the transferrin receptor.

Authors:  J F Collawn; L A Kuhn; L F Liu; J A Tainer; I S Trowbridge
Journal:  EMBO J       Date:  1991-11       Impact factor: 11.598

View more
  36 in total

1.  The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.

Authors:  John R Day; Carsten Münk; John C Guatelli
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.

Authors:  Eloísa Yuste; Jacqueline D Reeves; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.

Authors:  Virginie Sandrin; Delphine Muriaux; Jean-Luc Darlix; François-Loïc Cosset
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

6.  A tyrosine-based motif in the HIV-1 envelope glycoprotein tail mediates cell-type- and Rab11-FIP1C-dependent incorporation into virions.

Authors:  Mingli Qi; Hin Chu; Xuemin Chen; Junghwa Choi; Xiaoyun Wen; Jason Hammonds; Lingmei Ding; Eric Hunter; Paul Spearman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-01       Impact factor: 11.205

7.  New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.

Authors:  S Abigail Smith; Cynthia A Derdeyn
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

8.  Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail.

Authors:  Ajay K Bhatia; Rajnish Kaushik; Nancy A Campbell; Suzanne E Pontow; Lee Ratner
Journal:  Virology       Date:  2008-12-06       Impact factor: 3.616

Review 9.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Hidden messages in the nef gene of human immunodeficiency virus type 1 suggest a novel RNA secondary structure.

Authors:  Ofer Peleg; Edward N Trifonov; Alexander Bolshoy
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.